8ÀϱîÁö ¾ÆÅÂÁö¿ª ÀÓ»ó¹Ì»ý¹°Çз°¨¿° ºÐ¾ß Àü¹®°¡ ¾à 1õ ¸í ÇÑÀÚ¸®¿¡
Çѱ¹·Î½´Áø´Ü ÃֽŠºÐÀÚÁø´Ü Àåºñ·½ÅÁ¦Ç° ¼Ò°³, Áö½Ä °øÀ¯ ÄÜÅÙÃ÷ Á¦°ø
[º¸°ÇŸÀÓÁî] Çѱ¹·Î½´Áø´ÜÀº 8ÀϱîÁö ¼¿ï °³²±¸ ÄÚ¿¢½º¿¡¼ ÁøÇàµÇ´Â Á¦19Â÷ ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÓ»ó¹Ì»ý¹°°¨¿°Çмú´ëȸ(The 19th Asia Pacific Congress of Clinical Microbiology and Infection, ÀÌÇÏ APCCMI 2023)¿¡ Âü°¡ÇÑ´Ù°í 7ÀÏ ¹àÇû´Ù.
APCCMI´Â 2010³âºÎÅÍ ¾ÆÅÂÁö¿ª¿¡¼ °Ý³âÀ¸·Î °³ÃֵǴ ÀÓ»ó¹Ì»ý¹° ºÐ¾ßÀÇ ±ÇÀ§ ÀÖ´Â ÇÐȸ·Î 1000¿© ¸í ÀÌ»óÀÇ ÀÓ»ó¹Ì»ý¹°ÇÐ ¹× °¨¿° ºÐ¾ß Àü¹®°¡µéÀÌ ¸ð¿© ÃֽŠÁö°ßÀ» ¹ßÇ¥ÇÏ°í ÀÇ°ßÀ» ³ª´©´Â ±¹Á¦ ´ëȸ´Ù. 2021³â ½Ì°¡Æ÷¸£¿¡¼ÀÇ ¼º°øÀû °³ÃÖ¿¡ ÀÌ¾î ¿ÃÇØ´Â ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸÀÇ ÁÖ°üÀ¸·Î ¼¿ï¿¡¼ °³ÃֵƴÙ.
Çѱ¹·Î½´Áø´ÜÀº Çà»ç ù³¯ °¡Å縯ÀÇ´ë Áø´Ü°Ë»çÀÇÇаú À¯Àοµ ±³¼ö¸¦ ÃʺùÇØ ‘BK ¹ÙÀÌ·¯½º °¨¿° ºÐÀÚ Áø´ÜÀÇ ÇöÀç °úÁ¦’¸¦ ÁÖÁ¦·Î ¼¼¼ÇÀ» ÁøÇàÇÏ°í, ÀÌ¿µÈ£ Çѱ¹·Î½´Áø´Ü ºÐÀÚÁø´Ü»ç¾÷ºÎ ¸¶ÄÉÆà »ó¹«°¡ ‘ÀÌ½Ä È¯ÀÚ °ü¸®¿¡¼ CMV, EBV ¹× BKV ¹ÙÀÌ·¯½º ºÎÇÏ ¸ð´ÏÅ͸µ ¹× Ç¥ÁØÈÀÇ Á߿伺’¿¡ ´ëÇØ ¼Ò°³Çß´Ù.
Çà»ç ¸¶Áö¸· ³¯ÀÎ 8ÀÏ¿¡´Â ÀϺ»ÀÇ Satoshi Mitarai ¹Ú»ç(Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Japan)¸¦ ÃʺùÇØ ‘À̼ҴϾÆÁöµå, ¸®ÆÊÇǽŠ³»¼º ¹× ¸¶ÀÌÄÚ¹ÚÅ׸®¿ò ¾Æºñ¿ò º¹ÇÕü ºÐÀÚÁø´ÜÀÇ ÀÓ»óÀû °¡Ä¡’(Clinical value of the molecular diagnosis of isoniazid, rifampicin resistance, and Mycobacterium avium complex) ¸¦ ÁÖÁ¦·Î Çмú¼¼¼ÇÀ» ÁøÇàÇÒ ¿¹Á¤À̸ç, Ãæ³²´ëÀÇ´ë Áø´Ü°Ë»çÀÇÇаú ±è¼±¿µ ±³¼ö¸¦ ÃÊûÇØ ‘´Ù¾çÇÑ ÀÓ»ó °Ëü¸¦ ÀÌ¿ëÇÑ °áÇÙÀÇ ºÐÀÚÁø´Ü’¿¡ ´ëÇØ ³íÀÇÇÒ ¿¹Á¤ÀÌ´Ù.
ÀÌ ¿Ü¿¡µµ »çÈê°£ ¿ÀÇÁ¶óÀÎ ºÎ½º Àü½Ã¸¦ ÅëÇØ ÀüÀÚµ¿È ºÐÀÚÁø´Ü ½Ã½ºÅÛÀÎ cobas® 5800°ú ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º ¹× RSV¿¡ ´ëÇÑ ºÐÀÚÁø´Ü ±â¹Ý POC ÀåºñÀÎ cobas® Liat ½Ã½ºÅÛÀ» ÇÑÀÚ¸®¿¡¼ º¼ ¼ö ÀÖµµ·Ï Àü½ÃÇÑ´Ù.
Ŷ ÅÁ(Kit Tang) Çѱ¹·Î½´Áø´Ü ´ëÇ¥´Â ”·Î½´Áø´ÜÀº ºÐÀÚÁø´Ü ºÐ¾ßÀÇ ¸®´õÀÏ »Ó ¾Æ´Ï¶ó PCR °Ë»ç¿¡ ´ëÇÑ Æ¯Ç㸦 ȹµæÇÏ°í »ó¿ëÈ¿¡ ¼º°øÇØ PCR °Ë»ç¹ýÀÇ ¹ßÀü°ú Ç¥ÁØÈ¿¡ ±â¿©ÇÑ PCR ºÐ¾ßÀÇ ¼±±¸ÀÚ·Î 30³â ÀÌ»ó PCR ºÐ¾ß¿¡¼ Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ßÀ» À§ÇØ ³ë·ÂÇØ ¿Ô´Ù”¸ç “¿©±â¼ ¸ØÃßÁö ¾Ê°í °í°´°ú ȯÀÚ¸¦ À§ÇØ ´õ¿í °¡Ä¡ ÀÖ´Â ¼Ö·ç¼ÇÀ» ¾Ë¸®°í Á¦°øÇÏ´Â °Í¿¡ ÃÖ¼±À» ´ÙÇÏ°Ú´Ù”°í ¹àÇû´Ù.